66 results about "High-mobility group" patented technology

Methods are disclosed for treating an inflammatory skin condition in a subject. The methods comprise administering to a subject an HMGB antagonist, such as a high mobility group box (HMGB) A box or a biologically active fragment thereof, an antibody to HMGB or an antigen-binding fragment thereof, an HMGB small molecule antagonist, an antibody to TLR2 or an antigen-binding fragment thereof, a soluble TLR2 polypeptide, an antibody to RAGE or an antigen-binding fragment thereof, a soluble RAGE polypeptide and a RAGE small molecule antagonist.

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and / or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

In various embodiments, the present invention is drawn to antibodies or antigen-binding fragments thereof that bind to a vertebrate high mobility group box (HMGB) polypeptide, methods of detecting and / or identifying an agent that binds to an HMGB polypeptide, methods of treating a condition in a subject characterized by activation of an inflammatory cytokine cascade and methods of detecting an HMGB polypeptide in a sample.

Disclosed herein are methods and devices for stimulating an immune response to a disease in a subject, which involves passing sub-microsecond long pulses of electric fields having an amplitude between 5 kV / cm and 68 kV / cm through an abnormal growth of a subject sufficient to suppress myeloid-derived suppressor cell (MDSC) or regulatory T cell (Treg) production, increase adenosine triphosphate (ATP) or high mobility group box 1 (HMGB1) production, or stimulate dendritic cell activation in the subject.

This invention is directed to a method of using a therapeutic composition comprising a compound of an alpha-ketoalkanoic acid (pyruvate) and / or its derivatives for the treatment of cytokine-mediated inflammatory conditions. The compound is an alpha-ketoalkanoic acid, a physiologically acceptable salt of an alpha-ketoalkanoic acid, an ester of an alpha-ketoalkanoic acid, or an amide of an alpha-ketoalkanoic acid. A component for inducing and stabilizing the enol resonance form of the ester at physiological pH values is also disclosed. The cytokine-mediated inflammatory conditions are mediated by, for example, an “early” (Tumor Necrosis Factor (TNF), interleukin-1β (IL-1β)) or “late” (high mobility group B-1 (HMGB-1)) mediator of inflammation. Exemplary cytokine-mediated inflammatory conditions include, but are not limited to, local and systemic inflammation, inflammatory bowel disease (Crohn's disease and ulcerative colitis), rheumatoid arthritis, asthma (including status asthmaticus), sepsis or septic shock, also including inflammatory skin conditions, for example, psoriasis and eczema.

Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and / or therapeutic antibodies.

An adsorbent of high-mobility-group proteins (HMG protein) which can remove HMG protein in body fluid is disclosed. The adsorbent according to the present invention has a water-insoluble carrier on which (a) substance(s) having (a) hydrogen-bondable functional group(s) and / or (a) hydrophobic functional group(s) is(are) immobilized.

Methods and apparatus of providing a subject with post-operative, sustained-release of a biological agent within a synovial joint is disclosed. These methods involve securing a depot containing the biological agent to a ligament, tendon, muscle within the joint to provide sustained-release of the agent while allowing for normal joint articulation. This methodology may be utilized to provide for sustained-release of a biological agent useful in treating various traumas and disorders of the joint. Such biological agents include antagonists of inflammation-related proteins, such as TNF-α, IL-1β, IL-6, IL-8, NF-κB, High Mobility Group Box 1 (HMG-B1), IL-2, IL-15 and steroidal and non-steroidal anti-inflammatories. Other biological agents include anti-inflammatory cytokines such as IL-10, IL-4, IL-13, and TGF-β. The biological agents also include osteogenic and cartilage producing growth factors such as, but not limited to, BMP-2, BMP-4, BMP-6, BMP-7, BMP-8, and MIA CD-RAP. Finally, the biological agents include siRNA and / or therapeutic antibodies.

The invention belongs to a biological dosemeter of ionizing radiation, in particular to application of high mobility group box 1 (HMGB1) as a biological dosemeter of ionizing radiation. After isolated cells especial blood is radiated, the increase of HMGB1 content is proportional to received ionizing radiation dose to form certain dose-effect relation, and the ELISA (Enzyme-Linked Immuno Sorbent Assay) method and other simple, convenient and feasible methods can be adopted for rapid detection after 24 h of irradiation. Thus, the HMGB1 can be used as the biological dosemeter of ionizing radiation; moreover, the HMGB1 can be used for measuring the biological radiation dose of human bodies and animals exposed to ionizing radiation.

The invention relates to a fish DNA molecular labeling technique. The invention selects Sox gene HMG (High mobility group) conservative area as colony-molecular goal, designs unique degenerate goal, obtains DNA fragments of Sox genes which are different in numbers and species with PCR and agarose gel electrophoresis, and uses this specific DNA molecules to decide and analyze hereditary characteristic and hereditary connection of diversity fishes. The method can analyze fish hereditary connection quickly and exactly and can also be used in hereditary connection analysis of other animals.

The invention discloses a plasmid for silencing cytokine signal inhibitory factor 1 and expressing high mobility group B1 protein and tumor associated antigen and a preparation method thereof, which belongs to genetic engineering technology. According to the invention, based on a gene recombination method, a cytokine signal inhibitory factor 1 small interfering RNA fragment shSOCS1, a fusion genecoding sequence of NY-ESO-1and MAGE3, and a coding sequence of HMGB1 are connected in the same vector of pIRES-EGFP; respective expression is guaranteed to be correct; and a plasmid coexpressing shSOCS1, HMGB1 and tumor associated antigen is constructed. A new-generation dendritic cell vaccine prepared by the plasmid of the invention can induce high-efficiency immune response of CTL cells with almost no side effects, and can become safe and effective immunotherapy.

The invention provides a compound or reagent kit for predicting liver cancer prognoses. The compound comprises nucleic acid used for specific detection of the expression level and / or expression mode of a liver cancer prognostic marker. The liver cancer prognostic marker comprises HMGB2 expressed as SEQ ID NO.16, namely high mobility group protein. By means of the compound or reagent kit, the liver cancer prognoses can be effectively obtained, and preferentially, the liver cancer prognoses are effectively obtained in different stages.

The invention discloses a high-mobility group III-V semiconductor metal oxide semiconductor (MOS) interface structure, which comprises a monocrystalline substrate (101), a buffer layer (102) formed on the upper surface of the monocrystalline substrate (101), a quantum well bottom barrier layer (103) formed on the buffer layer (102), a high-mobility quantum well channel (104) formed on the quantumwell bottom barrier layer (103), a quantum well top barrier layer (105) formed on the high-mobility quantum well channel (104), an interface control layer (106) formed on the quantum well top barrierlayer (105), a high-K gate medium (107) formed on the interface control layer (106), and a metal gate structure (108) formed on the high-K gate medium (107) in turn from bottom to top. The structure realizes high carrier mobility and low interface state density simultaneously, and meets the requirement of a complementary metal oxide semiconductor (CMOS) technology on a high-performance group III-V semiconductor.

The invention provides a rice stress resistance-related OsHMGB3 gene which is separated and cloned from a rice DNA (deoxyribonucleic acid) fragment. The gene contains the conserved domain of the HMG (high-mobility group) gene family, and is an HMGB (high-mobility group box) type member of the gene family. The OsHMGB3 gene is expressed after being induced by polyethylene glycol (PEG), high salinity, low temperature, high temperature and abscisic acid (ABA), and the over-expressed OsHMGB3 can enhance the osmotic stress resistance of rice at the seedling stage, and is related to rice stress resistance. The rice gene can notably respond to stress, can be applied to plant breeding for stress resistance, and can enhance the stress resistance of plants.

The invention discloses a composition for preventing and treating radioactive intestinal injuries. The composition comprises ferulic acid converted according to dosage 10-9mg / kg of an experiment mouse. The composition can be prepared into a clinically acceptable dosage form. The composition has an effect of preventing and treating the radioactive intestinal injuries, and the prevention and treatment of the radioactive intestinal injuries refer to improvement of capillary vessel injuries in intestinal villi, promotion of intestinal crypt stem cell proliferation and differentiation, promotion ofmucous epithelial cell regeneration, improvement of a cell state and a function of a hemopoietic system of the irradiated mouse by influencing a Thbd-aPC signal pathway and adjustment of an inflammatory factor HMGB1 (high mobility group box 1).

The invention provides an application of high mobility group protein B2, in particular to an application of high mobility group protein B2 as a protein molecular marker for detecting liver cell carcinoma. Obvious differential expressions of the high mobility group protein B2 exist respectively in cancer cells of liver cell carcinoma and cells adjacent to the cancer cells, and thus whether a patient suffers from liver cell carcinoma can be detected based on the expression of the high mobility group protein B2 in the liver cells.

The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and / or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and / or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

The invention relates to in vitro method for quantitating the antibodies specific for High mobility group box I (HMGB1) contained in a sample, in particular a serum sample or a cerebrospinal fluid sample obtained from a patient, and the use of this method in the prognostic and / or diagnosis of neurological disorders. These methods are in particular applicable to the monitoring of the human immunodeficiency virus (HIV) infection of a subject who is known to be infected with HIV and in the prognostic and / or diagnostic of the state of progression of Acquired immune deficiency syndrome (AIDS) or the state of progression toward AIDS, in particular the state of progression or the state of progression toward neurological disorders associated with AIDS. Finally, the invention is also about method to determine the immune deficiency or level of immune activation of a patient, in particular a HIV-infected patient.

The invention discloses an HMBG (High Mobility Group Box) 1 modified bone tissue engineering bracket material and a preparation method thereof. The HMBG1 modified bone tissue engineering bracket material is prepared by crosslinking a signal molecule HMGB1 to a PLLA (Poly L Lactic Acid) nanofiber bracket by means of heparin (2) and a crosslinking molecule Di-NH2-PEG (Polyethylene Glycol) by using the PLLA nanofiber bracket manufactured by an electrostatic spinning technology as a matrix. According to the invention, various functions of recruitment, infiltration and mobility of cells are realized by the signal molecule, so that the material has good biocompatibility, and can be used to compose stem cells and further can be directly applied to bone tissue repair. The material is simple and accessible in process and good in repeatability.

The invention relates to a novel application of a medicine, and in particular relates to the novel application of amprenavir for preventing or treating ischemic cardiovascular and cerebrovascular diseases by inhibiting an expression of HMGB1 (High Mobility Group Box 1). During the application, the dosage of the amprenavir is controlled within 120mg to 6000mg, wherein the amprenavir within the dosage of 240mg to 3000mg is optimally selected.

The invention belongs to biotechnology field, and relates to quantitative RT(reverse transcription)-PCR (polymerase chain reaction) detection kit, in particularly to a kit for detecting high mobility group chicken protein B1 by real-time fluorescent quantitative reverse-transcription polymerase chain reaction. The kit comprises RT reaction liquid, reverse transcriptase of Moroni rat leukoviruses, RNA enzyme inhibitor, PCR liquid, heat-resisting DNA polymerase, standard substance and reference substance. The kit can obtain cDNA by RT of mRNA sample, and work with real-time fluorescence quantification PCR detection technology to precisely quantify the mRNA expression index of high mobility group chicken protein B1 in the detecting sample. The kit can be used to analyze the expressing of HMGB1 in tissue and viscera of the chicken and also used to detecting the change of the expression level of the HMGB1 in chicken cells in different conditions. The invention provides a quick, accurate and repeatable detection method for the expression level of HMGB1 in chicken cells.

The invention provides a rice stress resistance-related OsHMGB3 gene which is separated and cloned from a rice DNA (deoxyribonucleic acid) fragment. The gene contains the conserved domain of the HMG (high-mobility group) gene family, and is an HMGB (high-mobility group box) type member of the gene family. The OsHMGB3 gene is expressed after being induced by polyethylene glycol (PEG), high salinity, low temperature, high temperature and abscisic acid (ABA), and the over-expressed OsHMGB3 can enhance the osmotic stress resistance of rice at the seedling stage, and is related to rice stress resistance. The rice gene can notably respond to stress, can be applied to plant breeding for stress resistance, and can enhance the stress resistance of plants.

The invention relates to the field of biology and aims to provide application of high mobility group box (HMGB) protein and antibody to the preparation of an ostrea rivularis anti-infection immune preparation. The amino acid sequence of the protein is shown as the SEQ ID NO:2; the coding frame nucleotide sequence of the gene is shown as the SEQ ID NO:1; the application of the protein to the preparation of the ostrea rivularis anti-infection immune preparation is to immunize New Zealand white rabbits by using the protein so as to obtain polyclonal antiserum. According to the invention, the ostrea rivularis HMGB gene coding frame full sequence is obtained; the soluble HMGB protein product is expressed and purified by establishing a prokaryotic expression vector; and the polyclonal rabbit antiserum is prepared. The polyclonal rabbit antiserum has the effect of inhibiting inflammatory response caused by ostrea rivularis pathogeny RLO and gram negative bacteria LPS as well as necrobiosis and apoptosis.The invention relates to the field of biology and aims to provide application of high mobility group box (HMGB) protein and antibody to the preparation of an ostrea rivularis anti-infection immune preparation. The amino acid sequence of the protein is shown as the SEQ ID NO:2; the coding frame nucleotide sequence of the gene is shown as the SEQ ID NO:1; the application of the protein to the preparation of the ostrea rivularis anti-infection immune preparation is to immunize New Zealand white rabbits by using the protein so as to obtain polyclonal antiserum. According to the invention, the ostrea rivularis HMGB gene coding frame full sequence is obtained; the soluble HMGB protein product is expressed and purified by establishing a prokaryotic expression vector; and the polyclonal rabbit antiserum is prepared. The polyclonal rabbit antiserum has the effect of inhibiting inflammatory response caused by ostrea rivularis pathogeny RLO and gram negative bacteria LPS as well as necrobiosis and apoptosis.

Compositions and methods for identifying agents which 1) mimic salicyclic acid binding to human, animal and plant high mobility group box proteins or 2) alter activities of these HMGBs by binding in or around their salicyclic acid-binding sites and agents so identified are disclosed.

Elevated high mobility group A (HMGA) protein expression in human cancer cells, and especially human pancreatic cancer cells, is correlated with resistance to the chemotherapy agent gemcitabine. The present invention uses HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine. Significant increases in cell death in AT-sDNA transfected cells compared to non AT-rich sDNA treated cells were observed in both cell lines. The data indicates the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in human cancer treatment, and in particular human pancreatic cancer treatment.

The present invention provides a method of determining and treating amyotrophic lateral sclerosis (ALS) in a subject, comprising the following steps: (1) measuring a concentration of an autoantibody against high mobility group box 1 protein (HMGB1) in a biological sample from the subject; and (2) administering an effective amount of ALS-treating drug to the subject whose measured concentration of the autoantibody against HMGB1 is higher than 0.874 μg / ml.

Elevated high mobility group A (HMGA) protein expression in human cancer cells, and especially human pancreatic cancer cells, is correlated with resistance to the chemotherapy agent gemcitabine. The present invention uses HMGA-targeted AT-rich phosphorothioate DNA (AT-sDNA) aptamers to suppress HMGA carcinogenic activity. Cell growth of human pancreatic cancer cells (AsPC-1 and Miapaca-2) transfected with AT-sDNA were monitored after treatment with gemcitabine. Significant increases in cell death in AT-sDNA transfected cells compared to non AT-rich sDNA treated cells were observed in both cell lines. The data indicates the potential use of HMGA targeted DNA aptamers to enhance chemotherapy efficacy in human cancer treatment, and in particular human pancreatic cancer treatment.

Methods and kits for the diagnosis and prognosis of acute myeloid leukemia (AML) are described. These methods and kits are based on the assessment of the level of expression of the gene High Mobility Group AT-hook 2 (HMGA2), and optionally of the level of expression of at least one additional prognostic marker gene such as PRKC Apoptosis WT1 Regulator (PAWR), in a biological sample from an AML patient. High levels of expression of HMGA2 and PAWR in the sample are associated with poor disease prognosis, for example low probability of survival and / or increased risk of relapse, in AML patients, including in intermediate-risk AML patients. Methods and kits for the diagnosis of AMLs with TP53 mutations based on genes differentially expressed in AMLs with TP53 mutations relative to other AMLs also described.